Parlodel no longer to be sold for lactation suppression - safety concerns lead to withdrawal of drug by Sandoz Pharmaceuticals Corp
FDA Consumer, Nov, 1994
A drug manufacturer voluntarily stopped marketing a product for lactation suppression last August, shortly after FDA initiated action to withdraw the drug's approval for that use because of safety concerns.
The agency had received numerous reports of deaths and other serious adverse reactions to Parlodel (bromocriptine) in women taking the drug to stop their milk production. The reports included 31 women suffering strokes--9 fatal--and 63 women with seizures. Of these, 40 percent reported no other cause of the event.
There were also seven reports of heart attack--one fatal--and 16 hospitalizations for headache, severe high blood pressure, and other conditions. Other reports of such reactions have appeared in the medical literature.
- Most Popular Articles in Health
- Fuel your workout: exercisers who eat before they work out have more energy ...
- Soothe a dry, itchy scalp: 5 easy expert solutions
- Cocktails and calories: Beer, wine and liquor calories can really add up. ...
- The sour truth about apple cider vinegar - evaluation of therapeutic use
- The, six best supplements you've never heard of: these secret weapons can ...
- More »
Sandoz Pharmaceuticals Corp., which manufactures Parlodel, will continue to sell the drug for its other approved uses--to treat Parkinson's disease and acromegaly (enlargement of the bones of the nose, jaws, fingers, and toes caused by excess growth hormone). It is also approved for conditions associated with excess blood levels of the hormone prolactin, such as spontaneous flow of milk often accompanied by amenorrhea.
COPYRIGHT 1994 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group